Edit model card

20240309_am24_abstract_topic_model

This is a BERTopic model. BERTopic is a flexible and modular topic modeling framework that allows for the generation of easily interpretable topics from large datasets.

Usage

To use this model, please install BERTopic:

pip install -U bertopic

You can use the model as follows:

from bertopic import BERTopic
topic_model = BERTopic.load("djordan/20240309_am24_abstract_topic_model")

topic_model.get_topic_info()

Topic overview

  • Number of topics: 175
  • Number of training documents: 8265
Click here for an overview of all topics.
Topic ID Topic Keywords Topic Frequency Label
-1 Immunotherapy and Tumor Microenvironment - - - - 5 Immunotherapy and Tumor Microenvironment
0 Cancer Survival and Healthcare Access - - - - 3778 Cancer Survival and Healthcare Access
1
Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies - - - - 429 Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies
2 Glioblastoma research and treatment - - - - 186 Glioblastoma research and treatment
3 "3D Organoid Culture in Cancer Research" - - - - 168 3D Organoid Culture in Cancer Research
4 Kras G12C Inhibitors and Resistance - - - - 160 Kras G12C Inhibitors and Resistance
5
Acute Myeloid Leukemia Treatment and Drug Screening - - - - 154 Acute Myeloid Leukemia Treatment and Drug Screening
6 Spatial imaging of tissue microenvironments - - - - 120 Spatial imaging of tissue microenvironments
7 Prostate cancer and AR degradation - - - - 112 Prostate cancer and AR degradation
8 Parp Inhibition and DNA Damage Repair - - - - 110 Parp Inhibition and DNA Damage Repair
9 Pancreatic Ductal Adenocarcinoma (PDAC) Microenvironment - - - - 99 Pancreatic Ductal Adenocarcinoma Microenvironment
10 Topoisomerase 1 Inhibitors Adc Development - - - - 92 Topoisomerase 1 Inhibitors Adc Development
11 Hepatocellular Carcinoma Treatment Research - - - - 85 Hepatocellular Carcinoma Treatment Research
12 EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer - - - - 78 EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer
13 Glutamine Metabolism in Cervical Cancer - - - - 76 Glutamine Metabolism in Cervical Cancer
14
"Nanoparticle-based cancer treatment" - - - - 67 Nanoparticle-based cancer treatment
15 Bone metastasis in breast cancer - - - - 56 Bone metastasis in breast cancer
16 Microbiome and Immunotherapy in Cancer - - - - 54 Microbiome and Immunotherapy in Cancer
17 Triple Negative Breast Cancer (TNBC) - - - - 51 Triple Negative Breast Cancer
18
Oral Squamous Cell Carcinoma (OSCC) Research - - - - 48 Oral Squamous Cell Carcinoma Research
19 Melanoma therapy and Braf inhibitors - - - - 46 Melanoma therapy and Braf inhibitors
20 Immunomodulation of Glioblastoma with Sting Agonism - - - - 45 Immunomodulation of Glioblastoma with Sting Agonism
21
"Anticancer mechanisms of natural compounds" - - - - 41 Anticancer mechanisms of natural compounds
22 Renal Cell Carcinoma Subtypes - - - - 41 Renal Cell Carcinoma Subtypes
23
"Liquid Biopsy Using Urine and Plasma Samples" - - - - 40 Liquid Biopsy Using Urine and Plasma Samples
24 Award ceremony speech draft - - - - 39 Award ceremony speech draft
25
TCR-engineered therapy for cancer treatment - - - - 38 TCR-engineered therapy for cancer treatment
26 T-cell engagers for cancer treatment - - - - 38 T-cell engagers for cancer treatment
27 Colorectal cancer research - - - - 37 Colorectal cancer research
28 Obesity and breast cancer - - - - 36 Obesity and breast cancer
29 Ferroptosis in cancer treatment - - - - 36 Ferroptosis in cancer treatment
30 Trop2-targeted ADCs for cancer treatment - - - - 34 Trop2-targeted ADCs for cancer treatment
31 Hippo pathway inhibitors - - - - 34 Hippo pathway inhibitors
32 Immunotherapy in mice - - - - 33 Immunotherapy in mice
33
Clinical trials of immunotherapies - - - - 32 Clinical trials of immunotherapies
34 Immunity checkpoint inhibitors and resistance - - - - 29 Immunity checkpoint inhibitors and resistance
35 Pancreatic cancer research - - - - 29 Pancreatic cancer research
36 Drug combination screening - - - - 28 Drug combination screening
37
Pancreatic Cancer Research - - - - 27 Pancreatic Cancer Research
38 Her2 expression in solid tumors - - - - 26 Her2 expression in solid tumors
39 Smoking-induced lung cancer research - - - - 26 Smoking-induced lung cancer research
40
"Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer" - - - - 26 Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer
41 Prostate cancer research and treatment - - - - 25 Prostate cancer research and treatment
42 Cyclin-dependent kinase 2 inhibition in cancer therapy - - - - 25 Cyclin-dependent kinase 2 inhibition in cancer therapy
43
"Methylation Detection from Cell-Free DNA" - - - - 25 Methylation Detection from Cell-Free DNA
44 Medulloblastoma research and treatment - - - - 25 Medulloblastoma research and treatment
45 Single-cell RNA sequencing and chromatin accessibility analysis - - - - 24 Single-cell RNA sequencing and chromatin accessibility analysis
46
"MTA-PRMT5 Inhibitors for Cancer Treatment" - - - - 24 MTA-PRMT5 Inhibitors for Cancer Treatment
47 Anti-PD-1 therapy in NSCLC - - - - 24 Anti-PD-1 therapy in NSCLC
48 Immunomodulation with IL-18 and PD-1 antagonists - - - - 24 Immunomodulation with IL-18 and PD-1 antagonists
49 RMS and Pax3-Foxo1 Fusion Protein Research - - - - 24 RMS and Pax3-Foxo1 Fusion Protein Research
50
"Chromatin organization and gene regulation in breast cancer" - - - - 24 Chromatin organization and gene regulation in breast cancer
51 Multi-Cancer Early Detection Tests - - - - 23 Multi-Cancer Early Detection Tests
52
Mitochondrial dysfunction in cancer - - - - 23 Mitochondrial dysfunction in cancer
53 Cholangiocarcinoma research and treatments - - - - 23 Cholangiocarcinoma research and treatments
54 Immune cell analysis with cytof - - - - 23 Immune cell analysis with cytof
55
"Circulating Tumor DNA Monitoring in Cancer Treatment" - - - - 23 Circulating Tumor DNA Monitoring in Cancer Treatment
56 Cellular thermal shift assay (CTSA) for target engagement - - - - 22 Cellular thermal shift assay for target engagement
57 "FFPE Library Prep Methods" - - - - 21 FFPE Library Prep Methods
58
"Lung Cancer Classification and Targeting" - - - - 21 Lung Cancer Classification and Targeting
59 Immunotherapy biomarkers in cancer patients - - - - 20 Immunotherapy biomarkers in cancer patients
60 Colorectal cancer genomics and mutations - - - - 20 Colorectal cancer genomics and mutations
61 Epithelial-mesenchymal transition and plasticity in cancer - - - - 20 Epithelial-mesenchymal transition and plasticity in cancer
62 Electric fields for cancer treatment - - - - 19 Electric fields for cancer treatment
63 Cancer-associated fibroblasts in tumor microenvironment - - - - 19 Cancer-associated fibroblasts in tumor microenvironment
64
Prostate cancer research and diagnosis - - - - 19 Prostate cancer research and diagnosis
65
Acquired drug resistance and persister cells - - - - 19 Acquired drug resistance and persister cells
66
"EAC and Barrett's Esophagus Research" - - - - 19 EAC and Barrett's Esophagus Research
67
"Lung Cancer Research" - - - - 18 Lung Cancer Research
68
"Cachexia and Muscle Wasting in Cancer Patients" - - - - 18 Cachexia and Muscle Wasting in Cancer Patients
69 Cloud-based data governance for cancer research - - - - 17 Cloud-based data governance for cancer research
70 Ewing Sarcoma Research - - - - 17 Ewing Sarcoma Research
71
"Immunotherapy targeting Tregs" - - - - 16 Immunotherapy targeting Tregs
72
Nano-immunotherapy for cancer treatment - - - - 16 Nano-immunotherapy for cancer treatment
73
"Trial of T-1101 and T-1201 in Cancer Treatment" - - - - 16 Trial of T-1101 and T-1201 in Cancer Treatment
74 Radiation and Immunity in Cancer Treatment - - - - 16 Radiation and Immunity in Cancer Treatment
75 Immunotherapy and Neoantigens - - - - 15 Immunotherapy and Neoantigens
76 Aging and immune system in cancer - - - - 15 Aging and immune system in cancer
77
Progesterone and breast cancer - - - - 14 Progesterone and breast cancer
78
"Gut Microbiome in CRC Patients" - - - - 14 Gut Microbiome in CRC Patients
79 Hematopoiesis and Clonal Variants - - - - 14 Hematopoiesis and Clonal Variants
80
"Kinase Inhibition and Targeting" - - - - 14 Kinase Inhibition and Targeting
81 Paralog selective degraders for cancer therapy - - - - 13 Paralog selective degraders for cancer therapy
82
"Immunotherapy for Melanoma" - - - - 13 Immunotherapy for Melanoma
83 Genome-scale measurements for tumor normal benchmark - - - - 13 Genome-scale measurements for tumor normal benchmark
84 Immunotherapy for bladder cancer - - - - 13 Immunotherapy for bladder cancer
85 Hematopoietic Progenitor Kinase 1 Inhibition - - - - 13 Hematopoietic Progenitor Kinase 1 Inhibition
86
Variants of Uncertain Significance (VUS) - - - - 13 Variants of Uncertain Significance
87
"Colorectal cancer detection" - - - - 13 Colorectal cancer detection
88 Claudin18 Targeted Therapy - - - - 13 Claudin18 Targeted Therapy
89
"AI-based tumor purity analysis" - - - - 13 AI-based tumor purity analysis
90 Bispecific antibody development for cancer treatment - - - - 13 Bispecific antibody development for cancer treatment
91
"Genomic Variant Detection" - - - - 12 Genomic Variant Detection
92 Prostate cancer in African men - - - - 12 Prostate cancer in African men
93
"Microsatellite Instability and WRN Helicase Inhibition" - - - - 12 Microsatellite Instability and WRN Helicase Inhibition
94 Immunosuppression and antibody-enhancing drugs - - - - 12 Immunosuppression and antibody-enhancing drugs
95
"Immune Checkpoint Inhibitor Adverse Events" - - - - 12 Immune Checkpoint Inhibitor Adverse Events
96 Neuronal influence on cancer growth - - - - 12 Neuronal influence on cancer growth
97 "Uveal Melanoma and Selenoproteome Expression" - - - - 11 Uveal Melanoma and Selenoproteome Expression
98 HBV and HCC Treatment Studies - - - - 11 HBV and HCC Treatment Studies
99
Btk Inhibitors and Resistance Mechanisms - - - - 11 Btk Inhibitors and Resistance Mechanisms
100
"Tertiary Lymphoid Structures in Cancer Prognosis" - - - - 11 Tertiary Lymphoid Structures in Cancer Prognosis
101 Extrachromosomal DNA in cancer research - - - - 11 Extrachromosomal DNA in cancer research
102 Smarca2/4 degraders for cancer treatment - - - - 11 Smarca2/4 degraders for cancer treatment
103
"Epigenetic Regulators and Cancer Treatment" - - - - 11 Epigenetic Regulators and Cancer Treatment
104 Bispecific anti-egfr/cmet adc - - - - 11 Bispecific anti-egfr/cmet adc
105 Transposable elements and cancer - - - - 10 Transposable elements and cancer
106
"ER Degradation Therapy for Breast Cancer" - - - - 10 ER Degradation Therapy for Breast Cancer
107 Macrophage-based therapies in cancer - - - - 10 Macrophage-based therapies in cancer
108
"Genomic Alterations in NSCLC" - - - - 10 Genomic Alterations in NSCLC
109 Bladder Cancer Diagnosis and Monitoring - - - - 10 Bladder Cancer Diagnosis and Monitoring
110
"Genomic profiling for cancer diagnosis" - - - - 10 Genomic profiling for cancer diagnosis
111 TCR Repertoire in Cancer Patients - - - - 10 TCR Repertoire in Cancer Patients
112 Kras Vaccine Development - - - - 10 Kras Vaccine Development
113
"G-quadruplex Targeting Compound in Pancreatic Cancer Treatment" - - - - 9 G-quadruplex Targeting Compound in Pancreatic Cancer Treatment
114
Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer (MCRC) - - - - 9 Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer
115 Liquid biopsy for glioma monitoring - - - - 9 Liquid biopsy for glioma monitoring
116
Mismatch repair and immune checkpoint inhibitors - - - - 9 Mismatch repair and immune checkpoint inhibitors
117
"Immunomodulatory effects of mushroom consumption in prostate cancer." - - - - 9 Immunomodulatory effects of mushroom consumption in prostate cancer.
118 Nectin-4 targeted ADCs - - - - 9 Nectin-4 targeted ADCs
119 Single-cell gene expression technologies - - - - 9 Single-cell gene expression technologies
120
Head and neck cancer subtyping - - - - 9 Head and neck cancer subtyping
121 Cancer Vaccine Development - - - - 8 Cancer Vaccine Development
122 Proteomic analysis of cancer tissues - - - - 8 Proteomic analysis of cancer tissues
123
"Lymphoma Prognostics and Treatment Strategies" - - - - 8 Lymphoma Prognostics and Treatment Strategies
124
"Chemotherapy Resistance Mechanisms in Colorectal Cancer" - - - - 8 Chemotherapy Resistance Mechanisms in Colorectal Cancer
125 Cancer-associated fibroblasts research - - - - 7 Cancer-associated fibroblasts research
126
Condensate-based drug discovery - - - - 7 Condensate-based drug discovery
127
"Metabolism and Cancer Treatment" - - - - 7 Metabolism and Cancer Treatment
128 Stat3 degraders for cancer therapy - - - - 7 Stat3 degraders for cancer therapy
129 Melanoma research and embryonic development - - - - 7 Melanoma research and embryonic development
130
"Ovarian Cancer Biomarkers" - - - - 7 Ovarian Cancer Biomarkers
131
LncRNA and Promoter Regulation in Cancer - - - - 7 LncRNA and Promoter Regulation in Cancer
132 Immunotherapy in cancer treatment - - - - 7 Immunotherapy in cancer treatment
133
"Ferroptosis in Cancer Cells" - - - - 7 Ferroptosis in Cancer Cells
134
"Cdk4 Inhibitors and Breast Cancer Resistance" - - - - 7 Cdk4 Inhibitors and Breast Cancer Resistance
135 Radiation therapy and DNA damage response inhibitors - - - - 7 Radiation therapy and DNA damage response inhibitors
136 Liquid biopsy for cancer diagnosis and treatment response. - - - - 7 Liquid biopsy for cancer diagnosis and treatment response.
137 Brain Metastasis Survival Analysis - - - - 7 Brain Metastasis Survival Analysis
138
Molecular Biomarkers in Breast Cancer - - - - 7 Molecular Biomarkers in Breast Cancer
139
P53 and RPL22 in Cancer - - - - 7 P53 and RPL22 in Cancer
140 Colorectal cancer research - - - - 7 Colorectal cancer research
141
"Tumor Suppression Mechanisms" - - - - 7 Tumor Suppression Mechanisms
142 Radiation-induced salivary gland damage and regeneration - - - - 7 Radiation-induced salivary gland damage and regeneration
143
"Adenosine Signaling and Immunotherapy" - - - - 7 Adenosine Signaling and Immunotherapy
144 Sarcopenia and ICI in NSCLC - - - - 7 Sarcopenia and ICI in NSCLC
145 Ethnic disparities in lymphoma survival - - - - 7 Ethnic disparities in lymphoma survival
146 Liquid biopsy for lung cancer screening - - - - 7 Liquid biopsy for lung cancer screening
147
"KDM6A Loss in Urothelial Carcinomas" - - - - 7 KDM6A Loss in Urothelial Carcinomas
148 Immuno-oncology screens with CRISPR and RNA-seq - - - - 6 Immuno-oncology screens with CRISPR and RNA-seq
149 P53 Restoration Therapy - - - - 6 P53 Restoration Therapy
150 Immunometabolic targeting in cancer immunotherapy - - - - 6 Immunometabolic targeting in cancer immunotherapy
151
"Breast cancer recurrence and gene regulation" - - - - 6 Breast cancer recurrence and gene regulation
152 Head and neck squamous cell carcinoma (HNSCC) research - - - - 6 Head and neck squamous cell carcinoma research
153
"HCC Immune Cells Study" - - - - 6 HCC Immune Cells Study
154
"Pd-L1 IHC Scoring Methods" - - - - 6 Pd-L1 IHC Scoring Methods
155 Ovarian Cancer Glycosylation and Metastasis - - - - 6 Ovarian Cancer Glycosylation and Metastasis
156
"Ubiquitin-Proteasome System in Cancer Treatment" - - - - 6 Ubiquitin-Proteasome System in Cancer Treatment
157
Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma - - - - 6 Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma
158 Immunotherapy in Non-Small Cell Lung Cancer - - - - 6 Immunotherapy in Non-Small Cell Lung Cancer
159 Anlotinib + Chemo for Advanced Escc Treatment - - - - 6 Anlotinib + Chemo for Advanced Escc Treatment
160
"Myc Targeting Technologies" - - - - 6 Myc Targeting Technologies
161 Neuroblastoma Epigenetics Study - - - - 5 Neuroblastoma Epigenetics Study
162
"Metastasis and Genetic Alterations" - - - - 5 Metastasis and Genetic Alterations
163 T Cell Exhaustion and Stemness Programs - - - - 5 T Cell Exhaustion and Stemness Programs
164
Prostate cancer research - - - - 5 Prostate cancer research
165
"Lung Cancer Microenvironment Analysis" - - - - 5 Lung Cancer Microenvironment Analysis
166
"Pi3k/Akt Inhibitors in Breast Cancer" - - - - 5 Pi3k/Akt Inhibitors in Breast Cancer
167
"Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis" - - - - 5 Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis
168 Extracellular Vesicle Research in Ovarian Cancer - - - - 5 Extracellular Vesicle Research in Ovarian Cancer
169 Colorectal Cancer Secondary Malignancies in Young Adults - - - - 5 Colorectal Cancer Secondary Malignancies in Young Adults
170 Molecular Glues Targeting Cancer-Specific E3 Ligases - - - - 5 Molecular Glues Targeting Cancer-Specific E3 Ligases
171 Epigenetics and Cancer Research - - - - 5 Epigenetics and Cancer Research
172 Immunogenic neoantigens and NMD inhibition in cancer immunotherapy - - - - 5 Immunogenic neoantigens and NMD inhibition in cancer immunotherapy
173 Click Activated Prodrugs Against Cancer Platform - - - - 5 Click Activated Prodrugs Against Cancer Platform

Training hyperparameters

  • calculate_probabilities: False
  • language: None
  • low_memory: False
  • min_topic_size: 10
  • n_gram_range: (1, 1)
  • nr_topics: None
  • seed_topic_list: None
  • top_n_words: 10
  • verbose: True
  • zeroshot_min_similarity: 0.7
  • zeroshot_topic_list: None

Framework versions

  • Numpy: 1.25.2
  • HDBSCAN: 0.8.33
  • UMAP: 0.5.5
  • Pandas: 1.5.3
  • Scikit-Learn: 1.2.2
  • Sentence-transformers: 2.6.0.dev0
  • Transformers: 4.39.0.dev0
  • Numba: 0.58.1
  • Plotly: 5.15.0
  • Python: 3.10.12
Downloads last month
0
Inference Examples
This model does not have enough activity to be deployed to Inference API (serverless) yet. Increase its social visibility and check back later, or deploy to Inference Endpoints (dedicated) instead.